Cipla Overtakes GSK to Become Top Indian Pharma Company (India)
This article was originally published in PharmAsia News
Executive Summary
So far in 2007, Cipla has emerged ahead of its competitors to become the top pharmaceutical company in the Indian domestic market with a share of 5.17 percent. Its closest competition is GlaxoSmithKline at 4.89 percent. Local leaders Ranbaxy, Nicholas Piramal, and Zydus Cadila followed up in the third, fourth, and fifth positions respectively. When international sales were taken into account, it was Ranbaxy that came out on top with the highest overall revenues of any Indian pharmaceutical manufacturer. Ranbaxy took the spot from Dr. Reddy's Laboratories, which held the lead position up until two months ago. (Click here for more
You may also be interested in...
GSK Takes Lupin To Court To Block Generic Combivir Launch in the U.S.
MUMBAI - Europe's largest drugmaker GlaxoSmithKline has sued Indian drug maker Lupin for infringement of its patents for anti-AIDS drug Combivir in the U.S
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.